Review of sitagliptin phosphate: a novel treatment for type 2 diabetes

por Gallwitz, Baptist
Publicado 2007

Implications of Postprandial Glucose and Weight Control in People With Type 2 Diabetes: Understanding and implementing the International Diabetes Federation guidelines

por Gallwitz, Baptist
Publicado 2009

The evolving place of incretin-based therapies in type 2 diabetes

por Gallwitz, Baptist
Publicado 2010

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

por Gallwitz, Baptist
Publicado 2010

Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy

por Gallwitz, Baptist
Publicado 2012

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes

por Gallwitz, Baptist
Publicado 2013

Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin

por Gallwitz, Baptist
Publicado 2015

Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy

por Gallwitz, Baptist
Publicado 2016

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015

por Gallwitz, Baptist
Publicado 2015

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data

por Gallwitz, Baptist
Publicado 2018

Clinical Use of DPP-4 Inhibitors

por Gallwitz, Baptist
Publicado 2019

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

por Gallwitz, Baptist
Publicado 2022

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide

por Gallwitz, Baptist, Giorgino, Francesco
Publicado 2021

How Do We Continue Treatment in Patients With Type 2 Diabetes When Therapeutic Goals Are Not Reached With Oral Antidiabetes Agents and Lifestyle? Incretin versus insulin treatment

por Gallwitz, Baptist, Bretzel, Reinhard G.
Publicado 2013

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations

por Meier, Juris J., Gallwitz, Baptist, Giorgino, Francesco
Publicado 2021

Incretin-Based Therapies: Viewpoints on the way to consensus

por Nauck, Michael. A., Vilsbøll, Tina, Gallwitz, Baptist, Garber, Alan, Madsbad, Sten
Publicado 2009

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly

por Shaw, Jonathan E., Gallwitz, Baptist, Han, Jenny, Hardy, Elise, Schernthaner, Guntram
Publicado 2017

The incretin/glucagon system as a target for pharmacotherapy of obesity

por Del Prato, Stefano, Gallwitz, Baptist, Holst, Jens Juul, Meier, Juris J.
Publicado 2021

Dissociation of GLP-1 and insulin association with food processing in the brain: GLP-1 sensitivity despite insulin resistance in obese humans

por Heni, Martin, Kullmann, Stephanie, Gallwitz, Baptist, Häring, Hans-Ulrich, Preissl, Hubert, Fritsche, Andreas
Publicado 2015

Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications

por Fritsche, Andreas, Heni, Martin, Peter, Andreas, Gallwitz, Baptist, Kellerer, Monika, Birkenfeld, Andreas L., Häring, Hans-Ulrich, Wagner, Robert
Publicado 2020